Highlights Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
65.34 ^USD	+0.83%		-3.27%	-21.74%

Apr. 26	Cytokinetics Appoints Sung Lee as CFO	MT
Apr. 09	Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 05	MT
Cytokinetics Reports Positive Follow-On Data for Prospective Heart Medication; Shares Rise	Apr. 05	MT
Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session	Apr. 05	CI
Cytokinetics Q4 Net Loss Narrows, Revenue Decreases; 2024 Outlook Issued	Feb. 27	MT
Earnings Flash (CYTK) CYTOKINETICS INCORPORATED Reports Q4 Revenue $1.7M, vs. Street Est of $13.3M	Feb. 27	MT
Cytokinetics, Incorporated Provides Revenue Guidance for 2024	Feb. 27	CI
Cytokinetics, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Cytokinetics, Incorporated Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Novartis Interest in Cytokinetics Takeover Has Cooled	Jan. 11	MT
Correction: Market Chatter: Novartis Interest in Cytokinetics Takeover Has Cooled	Jan. 11	MT
Cytokinetics Shares Slide as Novartis Reportedly Shies Away From Deal	Jan. 11	DJ
Novartis drops pursuit of Cytokinetics - WSJ	Jan. 11	RE
Novartis Pursuit of Cytokinetics Reportedly Cools	Jan. 10	CI
Cytokinetics Shares Jump 16% After WSJ Report of Novartis Deal	Jan. 08	DJ
Novartis Reportedly in Advanced Talks to Buy Cytokinetics, Deal Possible This Week	Jan. 08	MT
Novartis in advanced talks to buy Cytokinetics- WSJ	Jan. 08	RE
Novartis Reportedly in Advanced Talks to Buy Cytokinetics	Jan. 08	CI
Cytokinetics heart drug succeeds in closely watched study, shares surge	Dec. 27	RE
Cytokinetics' heart disease drug meets main goal in study	Dec. 27	RE
Cytokinetics, Incorporated Announces Positive Results from Sequoia-Hcm, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy	Dec. 27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Highlights

Filters